CompanyNTLANasdaqCambridge, MA

Intellia Therapeutics

Intellia Therapeutics develops CRISPR gene editing treatments for severe diseases.

SEC EDGAR ClinicalTrials.gov intelliatx.com

424B4Sep 28Latest SEC filing

Sep 8Latest story

September 2026

FDA accepts Intellia's BLA for lonvo-z in hereditary angioedema, grants priority review

Sep 8Regulatory milestoneIntellia Therapeutics

Intellia secures up to $400 million credit facility from OrbiMed

Sep 4FinancingIntellia Therapeutics

August 2026

Intellia reports positive Phase 3 HAELO data for lonvo-z, resumes nex-z enrollment

Aug 6Quarterly updateIntellia Therapeutics